Coccidioidomycosis (Valley Fever) (Coccidioides spp.)
Overview
Plain-Language Overview
Coccidioidomycosis (Valley Fever) is an infection caused by breathing in spores of the fungus Coccidioides found in soil, mainly in the southwestern United States. It primarily affects the lungs, causing symptoms like cough, fever, and chest pain. Some people may experience fatigue and muscle aches, while others might have no symptoms at all. In rare cases, the infection can spread beyond the lungs to other parts of the body, such as the skin, bones, or brain, leading to more serious health problems. The illness can last for weeks to months and may require medical evaluation to confirm the diagnosis.
Clinical Definition
Coccidioidomycosis (Valley Fever) is a fungal infection caused by inhalation of arthroconidia from the dimorphic fungi Coccidioides immitis or Coccidioides posadasii. The primary pathology involves a pulmonary granulomatous infection that can range from asymptomatic to severe pneumonia. The disease is endemic to arid regions, especially the southwestern United States. Major clinical significance includes the potential for disseminated disease in immunocompromised hosts or certain ethnic groups, affecting skin, bones, joints, and the central nervous system. Diagnosis relies on clinical suspicion in endemic areas combined with laboratory and radiographic findings. The immune response involves cell-mediated immunity, which is critical for controlling infection. Complications include chronic pulmonary disease and meningitis.
Inciting Event
Inhalation of arthroconidia spores released from disturbed soil in endemic areas.
Exposure to dust storms or soil excavation activities in endemic regions.
Occupational activities such as construction, farming, or archaeology that aerosolize fungal spores.
Travel to or residence in arid desert climates with endemic Coccidioides spp.
Latency Period
Symptoms typically develop 1 to 3 weeks after inhalation of spores.
Pulmonary symptoms may appear within 7 to 21 days post-exposure.
Disseminated disease can manifest weeks to months after initial infection.
Asymptomatic infection may have an indeterminate latency before serologic detection.
Diagnostic Delay
Initial symptoms mimic community-acquired pneumonia, leading to misdiagnosis.
Lack of awareness of endemic exposure history delays suspicion.
Serologic tests may be negative early in disease, causing false reassurance.
Radiographic findings are nonspecific and often attributed to bacterial pneumonia.
Mild or asymptomatic cases do not prompt early diagnostic testing.
Clinical Presentation
Signs & Symptoms
Fever, cough, and chest pain are hallmark respiratory symptoms.
Fatigue and night sweats commonly accompany systemic illness.
Erythema nodosum presents as tender red nodules on the shins.
Arthralgia or arthritis may occur as part of immune response.
Weight loss and dyspnea can indicate more severe or disseminated disease.
History of Present Illness
Patients often present with fever, cough, and pleuritic chest pain progressing over days to weeks.
Constitutional symptoms include fatigue, night sweats, and weight loss.
Erythema nodosum or erythema multiforme may appear as immune-mediated skin manifestations.
Disseminated disease presents with bone pain, meningitis symptoms, or skin lesions after initial pulmonary illness.
Symptoms may fluctuate with periods of improvement and relapse.
Past Medical History
History of immunosuppressive conditions such as HIV/AIDS or organ transplantation.
Previous residence or travel to endemic areas increases pretest probability.
Prior episodes of pulmonary infections or unexplained chronic cough.
Pregnancy history, especially in the third trimester, increases risk of severe disease.
Use of corticosteroids or other immunosuppressants may worsen disease course.
Family History
No well-established heritable genetic syndromes linked to coccidioidomycosis susceptibility.
Familial clustering is rare but may reflect shared environmental exposures.
Certain ethnic groups with higher risk suggest possible genetic predisposition but no specific genes identified.
No known Mendelian inheritance patterns associated with disease severity or susceptibility.
Family history of immunodeficiency disorders may increase risk indirectly.
Physical Exam Findings
Fever and tachypnea are common during acute infection.
Rales or crackles may be heard on lung auscultation in pulmonary involvement.
Erythema nodosum or erythema multiforme can appear as skin manifestations.
Lymphadenopathy may be present in disseminated disease.
Chest wall tenderness can occur with pleuritic involvement.
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by a combination of clinical presentation and epidemiologic exposure in endemic areas. Confirmatory tests include serologic assays detecting IgM and IgG antibodies against Coccidioides antigens. Fungal culture or histopathologic identification of spherules in tissue samples provides definitive evidence. Chest imaging often shows pulmonary infiltrates or nodules consistent with fungal pneumonia. Molecular methods such as PCR may assist but are less commonly used.
Pathophysiology
Key Mechanisms
Inhalation of airborne arthroconidia from Coccidioides spp. leads to pulmonary infection and local inflammatory response.
Spherule formation in lung tissue causes granulomatous inflammation and tissue necrosis.
Cell-mediated immunity is critical for controlling infection and preventing dissemination.
Dissemination occurs via hematogenous spread to skin, bones, joints, and central nervous system in immunocompromised hosts.
Delayed hypersensitivity and immune complex formation contribute to systemic symptoms and erythema nodosum.
| Involvement | Details |
|---|---|
| Organs | Lungs are the main organ affected, presenting with pneumonia-like symptoms and possible cavitary lesions. |
Skin may be involved in disseminated disease, manifesting as erythema nodosum or verrucous lesions. | |
Central nervous system can be affected in disseminated coccidioidomycosis causing meningitis. | |
| Tissues | Pulmonary tissue is the primary site of infection where inhaled arthroconidia transform into spherules causing inflammation. |
Granulomatous tissue forms as a host response to contain fungal elements and prevent dissemination. | |
| Cells | Macrophages are key in phagocytosing Coccidioides spherules and initiating the immune response. |
T helper 1 (Th1) cells mediate protective immunity by producing interferon-gamma to activate macrophages. | |
Neutrophils contribute to early innate defense but are less effective against mature spherules. | |
| Chemical Mediators | Interferon-gamma is critical for activating macrophages to kill Coccidioides organisms. |
Tumor necrosis factor-alpha (TNF-alpha) promotes granuloma formation to contain infection. | |
Interleukin-12 (IL-12) drives differentiation of Th1 cells essential for cell-mediated immunity. |
Treatments
Pharmacological Treatments
Fluconazole
- Mechanism:
Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity.
- Side effects:
Hepatotoxicity
Rash
Gastrointestinal upset
- Clinical role:
First-line
Itraconazole
- Mechanism:
Blocks fungal 14-alpha-demethylase, impairing ergosterol synthesis and fungal cell membrane formation.
- Side effects:
Hepatotoxicity
Heart failure exacerbation
Gastrointestinal upset
- Clinical role:
First-line
Amphotericin B
- Mechanism:
Binds ergosterol in fungal cell membranes, creating pores that cause cell death.
- Side effects:
Nephrotoxicity
Infusion-related reactions
Electrolyte abnormalities
- Clinical role:
Second-line
Non-pharmacological Treatments
Supportive care including oxygen therapy for respiratory distress.
Surgical drainage of large pulmonary cavities or abscesses if complicated.
Avoidance of exposure to endemic dust in endemic regions to prevent infection.
Prevention
Pharmacological Prevention
No established antifungal prophylaxis is routinely recommended for healthy individuals.
Fluconazole prophylaxis may be used in high-risk immunocompromised patients to prevent dissemination.
Avoidance of immunosuppressive therapy during active infection reduces risk of progression.
Non-pharmacological Prevention
Avoiding exposure to dusty soil in endemic areas reduces infection risk.
Wearing masks and protective clothing during soil-disrupting activities helps prevent inhalation of spores.
Public health education about endemic regions and symptoms improves early diagnosis.
Screening high-risk populations such as immunocompromised patients in endemic areas aids early detection.
Outcome & Complications
Complications
Disseminated coccidioidomycosis involving skin, bones, or CNS is a serious complication.
Meningitis caused by Coccidioides is a life-threatening complication.
Pulmonary fibrosis can develop after severe or chronic infection.
Pleural effusion or empyema may complicate pulmonary disease.
Respiratory failure can occur in severe pulmonary involvement.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Histoplasmosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Histoplasmosis |
|---|---|
Exposure to arid soil in southwestern United States | Exposure to bat or bird droppings in Ohio and Mississippi River valleys |
Pulmonary nodules with possible cavitation and upper lobe infiltrates | Mediastinal lymphadenopathy and diffuse micronodular infiltrates |
Positive serology or culture for Coccidioides spp. | Positive urine or serum Histoplasma antigen test |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Tuberculosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Tuberculosis |
|---|---|
Pulmonary nodules or patchy infiltrates without classic fibrosis | Upper lobe cavitary lesions with fibrosis and calcified granulomas |
Negative acid-fast stain; positive fungal culture or serology | Positive acid-fast bacilli stain or culture from sputum |
Often self-limited or subacute respiratory symptoms with erythema nodosum | Chronic progressive symptoms with night sweats and weight loss |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Blastomycosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Blastomycosis |
|---|---|
Exposure to desert soil in southwestern United States | Exposure to moist soil and decaying wood in the Ohio and Mississippi River basins |
Spherules containing endospores on microscopy | Broad-based budding yeast on microscopy |
Primarily pulmonary symptoms with occasional erythema nodosum | Frequent skin and bone involvement with verrucous lesions |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Community-acquired bacterial pneumonia
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Community-acquired bacterial pneumonia |
|---|---|
Subacute onset with dry cough, low-grade fever, and patchy infiltrates | Acute onset with high fever, productive cough, and lobar consolidation |
Normal or mildly elevated neutrophils with negative bacterial cultures | Elevated neutrophils and positive sputum Gram stain |
No improvement with antibiotics; requires antifungal therapy | Rapid improvement with antibiotics targeting common bacteria |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Sarcoidosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Sarcoidosis |
|---|---|
Unilateral or patchy pulmonary infiltrates without prominent lymphadenopathy | Bilateral hilar lymphadenopathy with reticulonodular infiltrates |
Caseating granulomas with fungal spherules | Noncaseating granulomas without organisms |
Positive serology or culture for Coccidioides spp. | Elevated serum angiotensin-converting enzyme and negative fungal tests |